Lantern Pharma Inc.

Lantern Pharma Inc. is a clinical-stage biopharmaceutical company focused on oncology, leveraging artificial intelligence (AI), machine learning, and genomic data to accelerate and transform the drug discovery and development process for cancer therapies. The company's mission is to identify and develop novel cancer treatments more efficiently and cost-effectively. Its headquarters are located in Dallas, Texas, United States.

Lantern Pharma utilizes its proprietary AI platform, RADR®, which encompasses over 200 billion data points, to identify biologically relevant genomic signatures correlated with drug response. This platform helps to pinpoint cancer patients who are most likely to benefit from their compounds. The company's pipeline includes three lead small molecule drug candidates—LP-300, LP-184, and LP-284—which target solid tumors and blood cancers. Additionally, they have an antibody-drug conjugate (ADC) program spanning 12 cancer indications and advance programs through a subsidiary focused on central nervous system and brain cancers. They recently launched withZeta.ai, an AI co-scientist platform designed for rare cancer drug discovery and development.

Lantern Pharma became a publicly traded company in June 2020. Recent notable developments include the upcoming public demonstration of their withZeta.ai platform in April 2026, following its scientific debut. The company has also scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for amendments to its HARMONIC trial and reported positive Phase 1a data for LP-184 in advanced solid tumors. Panna L. Sharma serves as the Chief Executive Officer, President, and Director, leading the company's efforts to position itself as an AI-driven precision oncology firm aiming to reduce the time and cost associated with traditional cancer drug development.

Latest updates

Lantern Pharma Advances AI Co-Scientist Platform with ZetaSwarm and ZetaOmics

Event summary

  • Lantern Pharma unveiled a roadmap for withZeta.ai, introducing ZetaSwarm™ and ZetaOmics™ for AI-driven oncology research.
  • ZetaSwarm™ is designed as an autonomous multi-agent swarm intelligence layer, coordinating specialist AI agents for complex scientific queries.
  • ZetaOmics™ offers real-time computational biology and multi-omic analytics, integrating curated datasets like TCGA and GTEx.
  • Enterprise-grade features include workspace accounts, audit trails, and private knowledge bases for institutional deployments.
  • The roadmap aims to position withZeta.ai as a standalone commercial AI platform for the broader oncology research community.

The big picture

Lantern Pharma's roadmap for withZeta.ai marks a strategic shift towards integrating multi-agent AI reasoning with computational biology, addressing a gap in the current AI biomedicine landscape. The move aligns with the broader trend of AI-driven drug discovery and precision oncology, positioning Lantern to capture value in both internal R&D and external commercial deployments. The integration of ZetaSwarm and ZetaOmics aims to compress months of research into hours, potentially accelerating drug development timelines and reducing costs.

What we're watching

Platform Differentiation
How ZetaSwarm and ZetaOmics will differentiate withZeta.ai in the competitive oncology AI landscape.
Enterprise Adoption
The pace at which pharma and biotech institutions will adopt withZeta.ai's enterprise-grade capabilities.
Commercial Viability
Whether withZeta.ai can sustain revenue growth through software licensing and subscription models.

Lantern Pharma Transforms Drug Development with Real-Time AI Modeling Platform

Event summary

  • Lantern Pharma has expanded its predictBBB.ai platform into a real-time Large Quantitative Model (LQM) accessible via a web service.
  • The LQM provides comprehensive molecular characterization and development analytics, previously requiring specialized expertise and infrastructure, now available on-demand.
  • The platform processes data using a benchmark-validated model, ranking among the top 12 on the Therapeutic Data Commons leaderboard.
  • Lantern Pharma intends to monetize the platform through subscriptions, partnerships, and licensing arrangements.

The big picture

Lantern Pharma's move democratizes access to advanced molecular characterization, previously limited to large organizations, potentially accelerating drug discovery timelines and lowering development costs across the industry. This shift towards web-native, on-demand AI tools reflects a broader trend of digital transformation within the pharmaceutical sector, driven by the need for increased efficiency and precision. The platform's integration with withZeta.ai suggests a strategy to embed AI capabilities deeply within the drug development process, moving beyond standalone analytics.

What we're watching

Adoption Rate
The platform's success hinges on adoption by pharmaceutical and biotech companies, and the speed of integration into existing workflows will be a key indicator of its value proposition.
Competitive Landscape
While Lantern Pharma positions this as a first-of-its-kind service, competitors may emerge or existing cheminformatics providers could rapidly develop similar offerings, potentially eroding market share.
Subscription Model
The viability of the subscription-based model will depend on pricing, feature expansion, and the ability to retain customers amidst potential cost pressures within the drug development sector.

Lantern Pharma Opens AI Oncology Platform to Public, Targets Rare Cancer Research

Event summary

  • Lantern Pharma will publicly demonstrate its withZeta.ai AI platform on April 30, 2026, with sessions at 8:30 AM and 4:30 PM ET.
  • The demonstration follows the platform’s debut at the AACR 2026 and Nasdaq MarketSite.
  • withZeta.ai is designed to accelerate rare cancer research by integrating datasets and employing generative AI.
  • The platform utilizes a subscription-based commercial model with tiers for academic, enterprise, and individual researchers.

The big picture

Lantern Pharma’s unveiling of withZeta.ai represents a strategic shift towards leveraging AI to address the underserved market of rare cancers, a segment projected to exceed $15 billion by 2030. The company’s decision to forgo a curated demonstration and open the platform to public scrutiny signals a commitment to transparency and aims to establish credibility within the scientific community. This move positions Lantern Pharma to capitalize on the growing demand for AI-powered solutions in drug discovery, but also exposes the platform to immediate competitive assessment.

What we're watching

Adoption Rate
The success of withZeta.ai hinges on its adoption by researchers and institutions; initial subscription numbers and user engagement will be key indicators of long-term viability.
Competitive Landscape
While Lantern Pharma positions withZeta.ai as unique, the broader AI-driven drug discovery market is attracting significant investment; the platform's differentiation will be tested by emerging competitors.
Regulatory Scrutiny
As AI becomes more integrated into drug development, regulatory bodies will likely increase scrutiny; Lantern Pharma's ability to navigate evolving guidelines will impact withZeta.ai's commercialization.
CID: 3068